P-295 Retrospective cohort study of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer: A real-world data from 4 hospitals in Portugal
نویسندگان
چکیده
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide and in Portugal. Trifluridine-tipiracil (TAS-102) has shown significant overall survival benefit compared with placebo patients chemorefractory metastatic CRC (mCRC) C-TASK FORCE SUNLIGHT. This retrospective study aimed to investigate safety efficacy TAS-102 plus bevacizumab (TAS-Bevacizumab) monotherapy pretreated mCRC 4 hospitals Records refractory chemotherapy who initiated 1 hospital TAS-Bevacizumab different Portugal since 2018 March 2023 were retrospectively reviewed. Statistical analyses done using SPSS (v26). Progression-free curves estimated by Kaplan Meier method, comparisons logrank test. Hazard ratios corresponding 95% CIs Cox proportional hazard regression. In all analyses, a two tailed p-value less than 0.05 was deemed be significant. Totally, 31 received 22 TAS-Bevacizumab. The mean age at diagnosis 62 years old 51% male patients. Mutation RAS present 66% diagnosis, 38% had left-sided tumors 60% stage IV diagnosis. All previous lines chemotherapy, majority (66%) started third line 81% an ECOG PS 0-1. Median progression-free (PFS) 7.4 months group [95% confidence interval (CI), 6.4-9.3] 4.8 (hazards ratio 0.58; CI, 1.8-6.1). Although relatively higher incidence grade equal or superior 3 neutropenia observed both groups (32% TAS 45% TAS-Bevacizumab), febrile low (3.2% vs 4.7%). Fatigue important symptom during treatment 16.1% 0% this real-world setting, mCRC, bevacizumab, as monotherapy, associated clinically relevant improvement PFS tolerable toxicity, showed
منابع مشابه
Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study
BACKGROUND Capecitabine monotherapy is a treatment option for selected patients with metastatic colorectal cancer (mCRC) and is administered to up to 17% of patients. Data are limited with regard to adverse events and dosing practices associated with capecitabine monotherapy in real-world situations. OBJECTIVES The aim of this study was to provide real-world data on adverse event rates and do...
متن کاملRetrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
OBJECTIVE After approval of bevacizumab in Japan, post-marketing surveillance studies reported on safety. However, few reports have shown the efficacy of bevacizumab as used in daily practice. We evaluated the efficacy and safety of bevacizumab for metastatic colorectal cancer patients in daily practice. METHODS All unresectable metastatic colorectal cancer patients who began receiving bevaci...
متن کاملObservational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer
BACKGROUND There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve ...
متن کاملChemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer
The present observational cohort study was designed to elucidate the efficacy and safety profile of bevacizumab or cetuximab with chemotherapy as the first-line treatment in Chinese patients with metastatic colorectal cancer (mCRC). Clinical data were collected from a single-center registry study where mCRC patients received first-line fluoropyrimidine-based chemotherapy combined with either be...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2023
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2023.04.351